Effect of metformin on incidence, recurrence, and mortality in prostate cancer patients: integrating evidence from real-world studies
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Metformin use is linked to a reduced incidence of prostate cancer (PCa). This meta-analysis found no significant association with PCa recurrence or mortality, but duration of use may influence its protective effect.
Area Of Science
- Oncology
- Pharmacology
- Epidemiology
Background
- Metformin is a widely used antidiabetic drug.
- Previous research on metformin's effect on prostate cancer (PCa) risk has yielded inconsistent results.
- Clarifying this relationship is crucial for patient care and drug repurposing.
Purpose Of The Study
- To conduct a meta-analysis assessing metformin's impact on clinical outcomes in prostate cancer (PCa) patients.
- To investigate the potential dose-response relationship between metformin use and PCa risk.
- To synthesize existing evidence on metformin and PCa incidence, recurrence, and mortality.
Main Methods
- Systematic literature search across 10 electronic databases and 4 registries.
- Meta-analysis using a random-effects model to calculate combined relative risks (RRs) and 95% confidence intervals (CIs).
- Subgroup and sensitivity analyses performed to explore heterogeneity and specific factors.
Main Results
- Metformin use was associated with a statistically significant reduction in PCa incidence (RR: 0.82, 95% CI: 0.74-0.91).
- No significant association was found between metformin use and reduced PCa recurrence (RR: 0.97, 95% CI: 0.81-1.15) or mortality (RR: 0.94, 95% CI: 0.81-1.09).
- Subgroup analyses indicated reduced PCa incidence in cohort studies from Asia and Europe. A linear correlation was observed between metformin use duration and its protective effect.
Conclusions
- Metformin use is independently correlated with a reduced incidence of prostate cancer.
- Metformin does not appear to significantly impact PCa recurrence rates or mortality.
- The duration of metformin therapy may play a role in its observed protective effect against PCa incidence.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...